Non-executive Director resignation
BRISBANE, 24 March 2025
QBiotics Group Limited (QBiotics) announces that Mr. Hamish Corlett has resigned as a Non-executive Director with effect from today. Hamish has been a Non-executive Director of QBiotics since 9 April 2021.
Mr Corlett said, "I have greatly valued my time on the Board and working alongside a talented team advancing innovative science. The focus of my time on the Board was to assist in helping the Company scale and prepare for an initial public offering and listing (IPO). With the Company and the Board now in a strong position to move towards the next phase of growth, it is the right time to step down and make way for additional Board members. I am passionate about the mission of QBiotics and I am proud to have been involved over the last four years. I wish the Board and team every success in the future.”
On behalf of the Board, Non-executive Chairman, Mark Fladrich commented, "The Board has greatly benefitted from Hamish's skills, experience and strategic insights during his time as a Non-executive Director. We thank him for his valued contribution. While he is stepping away from the Board role, we look forward to keeping in touch given his ongoing involvement as a major shareholder."
—ends—
FURTHER INFORMATION
STEPHEN DOYLE, CEO & MANAGING DIRECTOR
communications@qbiotics.com
or
MEDIA ENQUIRIES
JANE LOWE, IR DEPARTMENT
jane.lowe@irdepartment.com.au or +61 411 117 774
ABOUT QBIOTICS
QBiotics is an unlisted public Australian life sciences company specialising in the discovery and development of novel cell signalling small molecules. QBiotics applies phenotypic screening to generate breakthrough innovation in the discovery of first in class solutions to challenging medical conditions. Our current clinical focus is on novel treatments for cancer and debilitating chronic wounds.
QBiotics’ lead oncology drug, tigilanol tiglate is currently in human clinical Phase II trials in Soft Tissue Sarcoma and Head and Neck Cancer. Tigilanol tiglate has received Orphan Drug Designation from the US FDA for the treatment of Soft Tissue Sarcomas. A veterinary formulation of tigilanol tiglate is registered and marketed as an oncology pharmaceutical, under the trade name STELFONTA®, in the USA, Europe, the UK and Australia.
QBiotics’ lead wound healing drug candidate, EBC 1013, is a small molecule targeting a range of wounds including chronic and acute wounds and burns. A first-in-human Phase I clinical development in patients with venous leg ulcers is open for recruitment.